Şunu aradınız:: parkinson (Maltaca - İngilizce)

parkinson)
parkinson’s disease)

ta’ parkinson)
parkinson’s disease)

mard ta' parkinson
parkinson’s disease

marda ta' parkinson
parkinson's disease

il-marda ta’ parkinson
parkinson’s disease

marda ta’ parkinson (aggravar)
parkinson’s disease (worsening)

aggravar tal-marda ta’ parkinson
worsening of parkinson’s disease

marda ta’ parkinson (aggravar) bradikajneżja
parkinson’s disease (worsening) bradykinesia

dimenzja assoċjata mal- marda ta’ parkinson
dementia associated with parkinson’s disease

marda ta ’ parkinson u dimenzja bil- korpi lewy
parkinson’ s disease and dementia with lewy bodies

marda ta ’ parkinson neupro għandu jitwaqqaf gradwalment.
parkinson’ s disease neupro should be discontinued gradually.

effikaċja klinika u sigurtà bil-marda ta’ parkinson
clinical efficacy and safety in parkinson’s disease

azilect jintuża fil-kura tal-marda ta' parkinson.
azilect is used to treat parkinson’s disease.

il-marda ta’ parkinson u dimenzja b’lewy bodies
parkinson’s disease and dementia with lewy bodies

stalevo jintuża għall-kura tal-marda ta’ parkinson.
stalevo is used for the treatment of parkinson’s disease.

cabergoline, lisuride u pergolide (għal marda ta ’ parkinson).
cabergoline, lisuride and pergolide (for parkinson’ s disease).

studji kliniċi f’dimenzja assoċjata mal-marda ta’ parkinson
clinical studies in dementia associated with parkinson’s disease

- funzjoni anormali tal- moħħ, sintomi bħall- parkinson, konvulżjoni
121 -increase in muscle tone, muscle weakness caused by an abnormal immune system response -abnormal brain function, parkinson-like symptoms, convulsion -sleepiness during infusion

dożi ta’ mediċini oħrajn għall-kura tal-marda ta’ parkinson
doses of other medicines to treat parkinson’s disease